Bepridil is highlighted as an effective rhythm control option for atrial fibrillation in Japan, though its use requires careful monitoring for QT prolongation and torsade de pointes, especially in patients with structural heart disease.
Answers are grounded in this paper and cite their sources.
Bepridil may support rhythm control in select Japanese AF patients with QT monitoring; leaves open randomized safety trials in structural heart disease.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hideo Mitamura (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: